Pharmaceutical

Health Canada approves Telix’s Illuccix label expansion

Health Canada has expanded the approved use of Telix Pharmaceuticals' Illuccix for patient selection in PSMA targeted radionuclide therapy.

Oct 8, 2024 - 04:00
Health Canada approves Telix’s Illuccix label expansion
Health Canada has expanded the approved use of Telix Pharmaceuticals' Illuccix for patient selection in PSMA targeted radionuclide therapy.
Read the original article

Tags:

Previous Article

ProductLife boosts drug development with IntiQuan acquisition

Next Article

OnKure and Reneo Pharmaceuticals complete merger

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Health records don’t always show when patients are dead. One researcher is trying to change that

Health records don’t always show when patients are dead...

Dec 15, 2023

Preterm birth and infant mortality measures in U.S. remain stubbornly high

Preterm birth and infant mortality measures in U.S. rem...

Nov 17, 2023

AbbVie gains FDA approval for EPKINLY in follicular lymphoma

AbbVie gains FDA approval for EPKINLY in follicular lym...

Jun 28, 2024